Sunesis Pharmaceuticals (SNSS) Misses Q3 Views

Sunesis Pharmaceuticals (NASDAQ: SNSS) reported Q3 EPS of ($0.37), $0.24 worse than the analyst estimate of ($0.13). Revenue for the quarter came in at $265 thousand versus the consensus estimate of $4.17 million.

For earnings history and earnings-related data on Sunesis Pharmaceuticals (SNSS) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Rivian reports record Q3 deliveries, beats estimates, shares rise
• Goldman Sachs Starts Prada SpA (1913:HK) (PRDSY) at Buy
• Kotak Upgrades Persistent Systems Ltd. (PSYS:IN) to Buy (1)